Sex-Specific Genetic Variants are Associated With Coronary Endothelial Dysfunction

Satoshi Yoshino, MD;* Rebecca Cilluffo, MD;* Megha Prasad, MD; Patricia J. M. Best, MD; Elizabeth J. Atkinson, MS; Tatsuo Aoki, MD, PhD; Julie M. Cunningham, PhD; Mariza de Andrade, PhD; Lilach O. Lerman, MD, PhD; Amir Lerman, MD

**Background**—Endothelial dysfunction is an early stage of atherosclerosis. Single-nucleotide polymorphisms (SNPs) have been associated with vascular dysfunction, cardiac events, and coronary artery remodeling. We aimed to detect SNPs associated with endothelial dysfunction and determine whether these associations are sex specific.

**Methods and Results**—Six hundred forty-three subjects without significant obstructive coronary artery disease underwent invasive coronary endothelial function assessment. We collected data from 1536 SNPs that had previously been associated with vasoreactivity, angiogenesis, inflammation, artery calcification, atherosclerotic risk factors, insulin resistance, hormone levels, blood coagulability, or with coronary heart disease. Coronary vascular reactivity was assessed by the percent change in coronary artery diameter ≤ −20% after an intracoronary bolus injection of acetylcholine on invasive coronary physiology study. SNPs significantly associated with coronary epicardial endothelial dysfunction were ADORA1, KCNO1, and DNAJC4 in the whole cohort, LPA, MYBPH, ADORA3, and PON1 in women and KIF6 and NFKB1 in men (P<0.01).

**Conclusions**—We have identified several significant SNPs that are associated with an increased risk of coronary endothelial dysfunction. These associations appear to be sex specific and may explain gender-related differences in development of atherosclerosis. (J Am Heart Assoc. 2016;5:e002544 doi: 10.1161/JAHA.115.002544)

**Key Words:** acetylcholine • coronary disease • endothelium • genetics

Coronary endothelial dysfunction (CED) is an early stage in the development of atherosclerosis and is an independent predictor of adverse cardiovascular outcomes. Sex has been identified as an independent factor contributing to cardiovascular disease morbidity and mortality and endothelial dysfunction, but the role of CED has not been fully explored.2,6

Sex plays a role in the development of atherosclerosis, but sex-specific genetic associations and the relationship with endothelial dysfunction have not been identified.7 Healthy women have been shown to have higher endothelium-dependent dilation when compared to their male counterparts, and the presence of cardiovascular risk factors has been associated with sex-specific effects on endothelium-dependent dilation.8 The Women’s Ischemic Syndrome Evaluation study also suggested that sex plays a role in development of atherosclerosis, reporting increased likelihood of diffuse plaque formation in women when compared to men who developed discrete coronary lesions.9 Moreover, men have been shown to have a greater atheroma burden with more eccentric atheroma and diffuse epicardial endothelial dysfunction than women, suggesting increased structural and functional epicardial abnormalities when compared to their female counterparts.10 The reason for this difference is not entirely understood, and may be affected by genetic variability among single-nucleotide polymorphisms (SNPs) and their association with early atherosclerosis and CED.10 Genetic variations have been thought to play a role in the development of cardiovascular disease, and recent studies have focused on defining the genes that are responsible.11–14 New loci associated with cardiovascular risk factors, subclinical indexes, and disease end points have provided important

DOI: 10.1161/JAHA.115.002544  Journal of the American Heart Association 1
insights that shed light on biologic pathways that may be involved in the development of cardiovascular disease. These can plausibly be targeted for prevention and treatment in the future. Identification of genotypic predictors of disease may enhance our understanding of molecular mechanisms underlying CED and the development of atherosclerosis. While several studies have focused on determination of genetic associations with cardiovascular disease, few have focused on genetic and sex-specific associations with endothelial dysfunction, a precursor of cardiovascular disease. We aimed to evaluate this genetic variability and determine the association of sex-specific SNPs with epicardial CED.

Methods

Patient Population

The study was performed at Mayo Clinic in Rochester, Minnesota. The study protocol was approved by the Mayo Clinic Institutional Review Board. Informed consent was obtained from each patient.

As described previously, cardiac catheterization and coronary microvascular function testing was performed on 643 patients enrolled between January 1993 and December 2010. The decision to pursue cardiac catheterization and invasive coronary physiology testing was made by the referring cardiologist. Patients presented with chest pain and had clinical indication for routine coronary angiography to rule out underlying coronary artery disease. All patients enrolled in the study had no evidence of obstruction of coronary arteries on coronary angiography. They then underwent a coronary physiology study to evaluate for coronary microvascular dysfunction.

All patients who met criteria to undergo a coronary physiology study were included in the study. Exclusion criteria included unstable angina pectoris, history of uncontrolled systemic hypertension that requires long-term therapy, valvular heart disease, left ventricular ejection fraction <40%, and/or significant endocrine disorders including diabetes, hepatic, renal, or inflammatory disease.

Study Protocol

Vasoactive medications were discontinued for at least 36 hours prior to catheterization. Eating, drinking, or tobacco use was discontinued for at least 12 hours prior to the procedure. Diagnostic coronary angiography was performed with a 6F or 7F guiding catheter using a standard femoral percutaneous approach. Nonionic contrast material was used. No nitroglycerin was given prior to the diagnostic procedure. Unfractionated intravenous heparin was administered for an activated clotting time of ≈250 s.

Coronary vascular reactivity was studied using a 0.014-inch Doppler tipped guidewire (FloWire: Volcano Corp, CA) in the left anterior descending coronary artery. Intracoronary infusion of incremental doses of acetylcholine to a maximum tolerable dose (10⁻⁶, 10⁻⁵, and 10⁻⁴ mol/L at 1 mL/min at 3-minute intervals) was given. Epicardial coronary artery endothelium-dependent function was calculated as the percent increase in coronary artery diameter, (CAD) in response to acetylcholine. The cut-off points were derived from the presence or absence of impaired epicardial endothelial function, defined as percent change in CAD (% CAD) to acetylcholine less than −20%.

Genomic Data and Blood Collection

As previously described, DNA was extracted from blood using the Mayo Clinic Biospecimens Accessioning and Processing facility. Pico Green analysis was run on all samples to assess quality. Samples were genotyped at the Mayo Genotyping Core facility using an Illumina custom GoldenGate panel (San Diego, CA). Per 96-well plate, there were 85 unique samples, 5 duplicate DNA samples, and 6 quality control CEPH samples. The 1536 tag SNPs represented genes with previously identified associations with coronary vasoreactivity, angiogenesis, inflammation, artery calcification, atherosclerosis risk factors, insulin resistance, female hormones, blood coagulation system, or prevalence of coronary heart disease (CHD). Of these, 242 SNPs were excluded from the analysis due to minor allele frequencies <5%, Hardy Weinberg Equilibrium, P-values <0.001, or SNP call rates <95% (ie, missing values for at least 5% of the subjects). The majority of SNPs failed because they were monomorphic or had a very low minor allele frequency. Genetic positions were listed in Build 36.

Statistic Methodology

All statistical analysis was performed using PLINK and SAS version 9.3 (SAS Institute Inc., Cary, NC). Categorical data were analyzed using the χ² test and continuous variables were analyzed using two-sample t test and summarized using mean±SD. Logistic regression was run using the end point of %CAD response to acetylcholine < −20 to test for genetic differences after adjusting for age, sex, diabetes, smoking status, and body mass index, assuming a log-additive genetic model. Models were run testing for an interaction between sex and each SNP to determine sex-specific associations.

Results

Baseline Characteristics

Overall, median age was 49.7±11.4 years. Median age of women was 51.4±10.9 years, while it was 46.6 years for...
The majority of patients were of European ancestry (93% white + 5.6% unknown and presumed white). Baseline characteristics are summarized in Table 1. Of women enrolled, 58% were postmenopausal. While only 8% of the population had diabetes, hypertension was present in 41%, dyslipidemia in 55%, and 13% were current smokers. Aspirin was used by 50%, 37% used calcium channel blockers, and 39% used lipid lowering drugs. Of women, 27% were using hormone replacement therapy.

**Coronary Epicardial Endothelial Dysfunction**

The %CAd induced by acetylcholine was lower in men than in women (Table 1). Diabetes and smoking were significantly higher in patients with abnormal endothelial function when compared to patients with normal endothelial function. Medication was similar between men and women.

### Table 1. Patient Characteristics

|                  | All      | Women   | Men     | P Value |
|------------------|----------|---------|---------|---------|
| **Age, y**       | 49.7 (11.4) | 51.4 (10.9) | 46.6 (11.7) | <0.001 |
| **Body mass index, kg/m²** | 29.1 (6.2) | 29.2 (6.8) | 28.9 (4.7) | 0.63    |
| **Postmenopausal** | 243 (58%) | 243 (58%) | — (—)   |         |
| **% change CAd (Ach)** | −15.1 (21.2) | −13.6 (20.3) | −17.9 (22.7) | 0.015   |

**Risk factor**

- **Diabetes mellitus**: 52 (8%) 28 (7%) 24 (11%) 0.049
- **Hypertension**: 264 (41%) 166 (39%) 98 (45%) 0.13
- **Dyslipidemia**: 353 (55%) 218 (52%) 135 (62%) 0.010
- **Family history**: 409 (65%) 271 (65%) 138 (66%) 0.77
- **Lipoprotein A**: 24.0 (31.0) 23.7 (30.5) 24.6 (32.3) 0.76
- **hsCRP, mg/dL**: 2.7 (24.0) 3.4 (29.5) 1.4 (3.5) 0.37
- **Homocysteine, μmol/L**: 8.0 (4.4) 7.8 (5.0) 8.4 (2.9) 0.12
- **Smoking**<0.001
  - **Never**: 326 (51%) 242 (57%) 84 (39%)
  - **Former**: 232 (36%) 146 (34%) 86 (40%)
  - **Current**: 83 (13%) 37 (9%) 46 (21%)

**Drugs**

- **Aspirin**: 326 (51%) 206 (48%) 120 (55%) 0.010
- **Calcium channel blockers**: 239 (37%) 150 (35%) 89 (41%) 0.12
- **Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker**: 104 (16%) 62 (15%) 42 (19%) 0.12
- **β-Blocker**: 186 (29%) 128 (30%) 58 (27%) 0.38
- **Diuretics**: 106 (16%) 85 (20%) 21 (10%) <0.001
- **Lipid-lowering drugs**: 248 (39%) 151 (35%) 97 (45%) 0.020
- **Estrogen replacement therapy**: 117 (27%) 117 (27%) — (—)         

Values are given as n (%) or mean (SD). P-value shows women vs men. Ach, acetylcholine; CAd, coronary artery diameter; hsCRP, high-sensitivity C-reactive protein.
associated with an increased risk of abnormal %CA d induced by acetylcholine (P < 0.01).

In men (Table 3), we found that rs17511046 was associated with 
ADORA1, rs3774933 and rs1599961 were associated with nuclear factor of κ light polypeptide gene enhancer in B-cell 1 gene (NF-κB1), and rs20456 is associated with both LOC100124373 and KIF6. Also, k6_39474093 is associated with KIF6. These SNPs were associated with increased risk of abnormal coronary artery dilation indicating epicardial endothelial dysfunction (P < 0.01). Only ADORA1 and NFKB1 SNPs showed significant differences between men and women. The strongest evidence for differences between men and women was seen in SNPs on LPA and PON1 (interaction P < 0.01) (Table 3).

Comparison of SNPs was also made by stratifying patients into 3 groups: men, premenopausal women, and postmenopausal women, in order to assess the effect of menopause on these findings. We find that certain SNPs remain significantly associated with macrovascular endothelial dysfunction in premenopausal women, with others found to be significant in postmenopausal women (Tables 4 and 5).

For example, rs12038000 was associated with the adenosine A3 receptor gene (ADORA3), rs16851008 with ADORA1, and k1_201395343 and rs16851020 with both ADORA1 and with myosin binding protein H gene (MYBPH) in postmenopausal women but not in premenopausal women (Tables S2 and S3). rs2237583 was significantly associated with PON1 in postmenopausal women but not premenopausal women, and rs7767084 was associated with LPA in premenopausal women but not in postmenopausal women. rs9365171, rs3798221, rs9364564, and rs7453899 were associated with LPA in both premenopausal women and postmenopausal women.

Table 2. SNPs Associated With Macrovascular/Epicardial Endothelial Dysfunction Significant Only Among Females

| Chr. | Significant SNP in Females | Position | Gene Region | Risk Allele X/Y | Overall Allele X Frequency | OR Overall | P Value Overall | OR Men | P Value Men | OR Women | P Value Women | OR Women | P Value | Sex | P Value SNP×Sex |
|------|----------------------------|----------|-------------|----------------|---------------------------|------------|----------------|--------|-------------|---------|---------------|---------|--------|-----|----------------|
| 9    | rs12038000                 | 111859362| ADORA3      | A/G            | 0.61                      | 1.30       | 0.0357         | 0.93   | 0.7307      | 1.54    | 0.0057*       | 0.0708  |        |     |                |
| 1    | rs16851008                 | 201387919| ADORA1      | G/A            | 0.87                      | 1.33       | 0.1066         | 0.79   | 0.3910      | 1.93    | 0.0077*       | 0.0354  |        |     |                |
| 1    | k1_201395343              | 201395343| ADORA1/ MYBPH| A/G           | 0.87                      | 1.28       | 0.1549         | 0.73   | 0.2538      | 1.94    | 0.0083*       | 0.0254  |        |     |                |
| 1    | rs16851020                 | 201400275| MYBPH/ ADORA1| C/A           | 0.87                      | 1.29       | 0.1502         | 0.70   | 0.2132      | 1.96    | 0.0070*       | 0.0182  |        |     |                |
| 6    | rs7767084*                 | 160882493| LPA*        | G/A            | 0.16                      | 1.32       | 0.0780         | 0.71   | 0.2483      | 1.73    | 0.0039*       | 0.0075* |        |     |                |
| 6    | rs9365171                  | 160901726| LPA         | A/C            | 0.35                      | 1.37       | 0.0118         | 0.99   | 0.9691      | 1.65    | 0.0016*       | 0.0571  |        |     |                |
| 6    | rs3798221*                 | 160918138| LPA*        | T/G            | 0.19                      | 1.58       | 0.0023         | 0.80   | 0.4244      | 2.08    | 0.00004*      | 0.0061* |        |     |                |
| 6    | rs9364564*                 | 160919030| LPA*        | A/G            | 0.18                      | 1.50       | 0.0134         | 0.77   | 0.3854      | 2.00    | 0.0004*       | 0.0097* |        |     |                |
| 6    | rs7453899                  | 160930756| LPA         | T/A            | 0.35                      | 1.35       | 0.0167         | 1.00   | 1.0000      | 1.60    | 0.0029*       | 0.0848  |        |     |                |
| 6    | rs35600881                 | 160946754| LPA         | A/G            | 0.23                      | 1.50       | 0.0046         | 0.95   | 0.8481      | 1.79    | 0.0006*       | 0.0487  |        |     |                |
| 6    | rs13202636                 | 160949718| LPA         | G/A            | 0.23                      | 1.49       | 0.0053         | 0.95   | 0.8481      | 1.78    | 0.0007*       | 0.0520  |        |     |                |
| 6    | rs1321195                  | 161004146| LPA         | T/C            | 0.13                      | 1.48       | 0.0256         | 0.80   | 0.4877      | 1.90    | 0.0019*       | 0.0267  |        |     |                |
| 7    | rs2237583*                 | 94788113*| PON1*       | G/A            | 0.70                      | 1.15       | 0.3002         | 0.70   | 0.0898      | 1.63    | 0.0068*       | 0.0030* |        |     |                |

OR indicates odds ratio; SNPs, single-nucleotide polymorphisms.

*SNPs both significant in sex and SNP×Sex.
especially estrogen. Estrogen contributes to regulation of homeostasis, which may be regulated by sex hormones, a plausible association that plays a crucial role in vascular and PON1.

Genetic Polymorphisms in Endothelial Function
Yoshino et al
DOI: 10.1161/JAHA.115.002544
Journal of the American Heart Association

Discussion
The current study demonstrates sex-specific differences in SNPs and overlap region in some genes associated with epicardial CED in humans. These observations may explain differences in the propensity for development of early atherosclerosis between men and women and may have potential sex-specific therapeutic implications.

Genetic Associations in Women
In women, variations within ADORA3, ADORA1, MYBPH, LPA, and PON1 genes were associated with epicardial CED. This is a plausible association that plays a crucial role in vascular homeostasis, which may be regulated by sex hormones, especially estrogen. Estrogen contributes to regulation of vascular tone, modulates recruitment of circulating cells, affects platelet function, and plays a role in processes responsible for vascular repair. Gene variants in women modulate the function of estrogen, its receptors, and are implicated in aspects of cardiovascular inflammation, platelet function, and vascular repair.

Table 4. Genes With Significant SNPs in Men for Macrovascular Endothelial Dysfunction

Moreover, risk associated with LPA, PON1, and KCNQ1 variants affecting CED may be mediated through dysfunction in lipid metabolism. LPA risk alleles correlate with high plasma lipoprotein (a), which is associated with atherosclerotic vascular disease leading to CHD and may be thrombogenic. It inhibits fibrinolysis, accumulates in the vascular wall in atherosclerotic lesions, and may proliferate in human smooth muscle cells. PON1 exerts anti-atherogenic effects by protecting low-density lipoproteins against oxidation, which has been implicated in oxidative stress and coronary spasm. Thus, PON1 is associated with ox-low-density lipoprotein, which is associated with CED. KCNQ1 SNPs are associated with type 2 diabetes mellitus via a reduction in insulin secretion and higher fasting glucose. This may affect lipid metabolism in patients with type 2 diabetes and CHD.

Adenosine plays an important role in cardiac reperfusion response to ischemia. Variants in adenosine receptor genes including ADORA3 and ADORA1 may predict cardiac response to ischemia or injury. Upregulation of adenosine A3 receptors mRNA upon preconditioning is sex specific and depends on a woman’s menstrual cycle. In this study, the gene region of A1 receptors was alike in both women and men. Our study suggests that sex-specific SNPs on ADORA3 relate to epicardial CED and that ADORA1 polymorphisms play a sex-specific role in endothelial function, depending on the variation of the SNP.

Myosin binding protein H (MYPH) was also associated with epicardial CED in women. It is known that MYPH is expressed in ventricular Purkinje cells, but how MYPH gene mediates coronary epicardial endothelial function has yet to be elucidated. While little is known about MYPH and its association with coronary epicardial endothelial function, awareness of various genetic polymorphisms associated with epicardial CED is important since further studies on these genes may implicate a mechanism explaining this association.

Estrogen likely plays a significant role in explaining these findings and may partially explain the sex-specific differences.
Several genetic variations were noted in postmenopausal women but not premenopausal women. On the other hand, several genetic variations do not appear to be associated with menopausal status, and rather simply female sex. Additional investigation to further define the association with menopause is necessary.

**Genetic Associations in Men**

In men, genetic variations within \textit{ADORA1}, \textit{NFKB1}, \textit{LOC 100124373}, and \textit{KIF 6} genes are associated with epicardial CED. Gene variants related with the activity of nitric oxide synthase itself, angiogenesis, and inflammation modify CED in men in our study. These SNPs in men may mediate testosterone or its receptors and have adverse effects on cardiovascular morbidity and mortality.\textsuperscript{35}

Nuclear factor-\(\kappa\)B denotes a family of transcription factors involved in both pro-inflammatory and anti-inflammatory processes in atherogenesis.\textsuperscript{36} Polymorphisms in \textit{NFKB1} promoter are associated with an increased risk of CHD and heart failure.\textsuperscript{36} Inflammatory mechanisms affect all phases of coronary artery disease. Errors in genes encoding inflammatory or anti-inflammatory molecules are candidates for increasing risk of developing complications from coronary artery disease.\textsuperscript{36} There are sex-specific variations in NF-\(\kappa\)B activity, which may play a role in development of CED and atherosclerosis.\textsuperscript{37,38}

It is important to note the overlap in gene regions between women and men in our study. We found overlap of gene region in \textit{ADORA1} and \textit{KIF6} without duplication of SNPs. The kinesin family member 6 gene encodes an intracellular protein, which transports cellular cargo and is expressed in coronary endothelial cells.\textsuperscript{39} The association between \textit{KIF6} polymorphism and increased risk of CHD in male patients has been previously described.\textsuperscript{40} Arg\textsuperscript{719} allele of \textit{KIF6} was associated with increased risk of CHD and myocardial infarction in populations of healthy women with low prevalence of CHD.\textsuperscript{30} \textit{KIF6} polymorphisms may be involved in interrupting intracellular transport in endothelial cells in women or men depending on the SNPs predisposing to development of CED and CHD.

**Limitations**

Our study has several inherent limitations. First, this is a cross-sectional study in a unique patient population with early coronary atherosclerosis as defined by endothelial dysfunction. Further studies are needed to determine why a significant variant might have an effect in males and not in females with similar cardiovascular risk factors.

While most SNPs that we identified as significantly associated with early coronary atherosclerosis characterized by CED lie within currently presumed noncoding intronic sequences, there are several potential mechanisms that could explain their association. These SNPs may be in linkage disequilibrium with promoter SNPs that have not yet been identified or that were not genotyped in this study.\textsuperscript{41} Furthermore, these intronic SNPs may have promoter functions that have not yet been identified, and intronic variants may potentially affect receptor function through alternative splicing mechanisms\textsuperscript{41} SNPs in the 5' upstream region could play a significant role affecting gene transcription.

Additionally, the number of tests performed is another limitation of the study. We have performed a large number of tests and it is possible that these results are significant purely by chance. Further studies are necessary to confirm these findings.

**Conclusions**

The current study reports for the first time the association between sex-specific gene variants and physiological functional abnormalities related to early coronary atherosclerosis in humans characterized by epicardial endothelial dysfunction in coronary arteries. The study may help explain sex-specific differences in development of coronary endothelial function and atherosclerosis.
Sources of Funding

This work was supported by the National Institutes of Health (NIH Grant HL-92954 and AG-31750 to A. Lerman) and P30CA15083 (Mayo Clinic Cancer Center) and CTSA Grant Number KL2 RR024151 to P. J. M. Best. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. S. Yoshino was supported by Fukuda Foundation for Medical Technology, Japan.

Disclosures

None.

References

1. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J. 2012;33:2771–2782b.

2. Wang J, Bingaman S, Huxley VH. Intrinsic sex-specific differences in microvascular endothelial cell phosphodiesterases. Am J Physiol Heart Circ Physiol. 2010;298:H1144–H1154.

3. Ruggiero D, Paolillo S, Ratta GD, Marinello A, Formisano T, Pellegrino AM, Filardi PP. Endothelial function as a marker of preclinical atherosclerosis: assessment techniques and clinical implications. Monaldi Arch Chest Dis. 2013;80:106–110.

4. Ghanavatian S, Diep LM, Barany P, Heimburger O, Seeberger A, Stenvinkel P, Rohani M, Agewall S. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. Angiology. 2014;65:443–449.

5. Garcia MM, Lima PR, Correia LC. Prognostic value of endothelial function in patients with atherosclerosis: systematic review. Arq Bras Cardiol. 2012;99:857–865.

6. O’Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med. 2011;365:2098–2109.

7. Spence JD, Pilote L. Importance of sex and gender in atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2012;60:862–870.

8. Brar V, Gill S, Cardillo C, Tesauro M, Panza JA, Campia U. Sex-specific effects of cardiovascular risk factors on endothelial dysfunction in middle-aged women and men. PLoS One. 2015;10:e0121810.

9. Baier Merz CN, Shaw LJ, Reis SE, Tregouet DA, Breslow JL, Par正当 TJ, Johnson BD, Bittner V, Kelsey SF, Olson M, Johnson HD, Levey AI, Markus HS, Kostulas K, Dichgans M, Berger K, Kuhlenbaumer G, Ringelstein EB, Stoll M, Seedorf U, Rothwell PM, Powell JT, Kuhnemann H, Onundarson PT, Valdimarsson E, Matthiasson SE, Gudbjartsson DF, Thorgeirsson G, Quyyumi AA, Watkins H, Farrow M, Thorsteinsdottir U, Stefansson K. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2016;69:937–947.

10. Ito T, Yasue H, Yoshimura M, Nakayama S, Nakayama M, Shimazaki Y, Harada E, Mizuno Y, Kawanoh H, Ogawa H. Paraoxonase gene PON1 Q192R polymorphism is associated with coronary artery spasm. Hum Genet. 2002;110:89–94.

11. Lavo S, McNamara DM, Kukulski T, Wos S, Velazquez EJ, Ardlie K, Novak GD, Lavi S, McConnell JP, Lavi R, Barsness GW, Rihal CS, Nissen SE, Tajik AJ. Epicardial vasomotor responses to acetylcholine in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol. 2000;35:1654–1660.

12. Oliphant A, Barker DL, Stuelpnuller DJ, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques. 2002;suppl:56–58, 60-1.

13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PJ, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–575.

14. Villar IC, Hobbs AJ, Aihlawali A. Sex differences in vascular function: implication of endothelin-derived hyperpolarizing factor. J Endocrinol. 2008;197:447–462.

15. Villa M, Best PJ. Implications for reproductive medicine: sex differences in cardiovascular disease. Sex Reprod Menopause. 2011;9:21–28.

16. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patil RS, Gudnason T, Jones GT, van Rij AJM, Eapen DJ, Baas AF, Tregouet DA, Morange PE, Emmerich J, Lindblad B, Gottsater A, Kiemeny LA, Lindholt JS, Sakalihasan N, Ferrell RE, Carey DJ, Elmore JR, Tsao PS, Grupen N, Jorgensen T, Wittte DR, Hansen T, Pedersen O, Pola R, Gaetani E, Maggiorotto HB, Wijmenja C, Tromp G, Ronkainen A, Ruiogruk YM, Blankenstein JD, Mueller T, Wells PS, Corral J, Soria JM, Souto JC, Peden JF, Jalilalizadeh S, Mayosi BM, Keavney B, Strawbridge RJ, Sabater-Lleal M, Gertow K, Baldarssare D, Nykonsen K, Raourama R, Smit AJ, Mannarino E, Giral P, Trelori M, de Faire U, Humphries SE, Hamsten A, Haraldsdottir V, Olafsson I, Magnusson J, Samani NJ, Levey AI, Markus HS, Kostulas K, Dichgans M, Berger K, Kuhlenbaumer G, Ringelstein EB, Stoll M, Seedorf U, Rothwell PM, Powell JT, Kuhnemann H, Onundarson PT, Valdimarsson E, Matthiasson SE, Gudbjartsson D, Thorgerdsson G, Goyummi AA, Watkins H, Farrow M, Thorsteinsdottir U, Stefansson K. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2010;60:722–729.

17. Chen Z, Yin Q, Ma G, Oian Q. KCNQ1 gene polymorphisms are associated with lipid parameters in a Chinese Han population. Cardiovasc Diabetol. 2010;9:35.

18. Tang Z, Diamond MA, Chen JM, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purczycki A, Wagner J, McNamara DM, Kukulski T, Wos S, Velazquez EJ, Ardlie K, Feldman AM. Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. Clin Pharmacol Ther. 2007;82:435–440.

19. von Ameln CA, EBrich SM, Timmner M, Riepe MW. Gender-dependent hypoxic tolerance mediated via gender-specific mechanisms. J Neurosci Res. 2002;68:84–88.

20. Schiaffino S. Protean patterns of gene expression in the heart conduction system. Circ Res. 1997;80:749–750.

21. Vaccarino V, Badimon L, Corti R, de Wit C, Donadubt M, Hall A, Koller A, Marzilli M, Pries A, Bugiardini R. Ischaemic heart disease in women: are there
sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. *Cardiovasc Res*. 2011;90:9–17.

36. Santos DG, Resende MF, Mill JG, Mansur AJ, Krieger JE, Pereira AC. Nuclear factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure. *BMC Med Genet*. 2010;11:89.

37. Dale E, Davis M, Faustman DL. A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response. *Adv Physiol Educ*. 2006;30:152–158.

38. Vina J, Gambini J, Lopez-Grueso R, Abdelaziz KM, Jove M, Borras C. Females live longer than males: role of oxidative stress. *Curr Pharm Des*. 2011;17:3959–3965.

39. Povel CM, Boer JM, Onland-Moret NC, Dolle ME, Feskens EJ, van der Schouw YT. Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study. *Cardiovasc Diabetol*. 2012;11:133.

40. Peng P, Lian J, Huang RS, Xu L, Huang Y, Ba Y, Yang X, Huang X, Dong C, Zhang L, Ye M, Zhou J, Duan S. Meta-analyses of KLF6 Trp719Arg in coronary heart disease and statin therapeutic effect. *PLoS One*. 2012;7:e50126.

41. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R. Polymorphisms of KDR gene are associated with coronary heart disease. *J Am Coll Cardiol*. 2007;50:760–767.
## Table S1: Patient characteristics

|                   | All n=643 | Premenopausal n=178 | Postmenopausal n=426 | Men n=217 | P-value |
|-------------------|-----------|---------------------|----------------------|-----------|---------|
| **Age, years**    | 49.7 (11.4) | 43.8 (9.1)          | 56.9 (8.6)           | 46.6 (11.7) | <0.001  |
| **Body Mass Index, kg/m²** | 29.1 (6.2) | 29.1 (7.0)          | 29.1 (6.6)           | 28.9 (4.7) | 0.91    |
| % change CAd (Ach) | -15.1 (21.2) | -12.0 (20.4)        | -14.9 (20.1)         | -17.9 (22.7) | 0.022   |
| **Risk Factor**   |           |                     |                      |           |         |
| Diabetes Mellitus | 52 (8%)   | 12 (7%)             | 16 (7%)              | 24 (11%)  | 0.16    |
| Hypertension      | 264 (41%) | 52 (29%)            | 112 (46%)            | 98 (45%)  | <0.001  |
| Dyslipidemia      | 353 (55%) | 72 (41%)            | 145 (60%)            | 135 (62%) | <0.001  |
| Family History    | 409 (65%) | 113 (65%)           | 156 (66%)            | 138 (66%) | 0.96    |
| LipoProtein A     | 24.0 (31.0) | 22.2 (28.2)       | 25.1 (32.7)          | 24.6 (32.3) | 0.68    |
| hsCRP, mg/dL      | 2.7 (24.0) | 5.3 (43.5)          | 1.9 (2.8)            | 1.4 (3.5) | 0.30    |
| Homocysteine, umol/L | 8.0 (4.4) | 7.5 (4.7)          | 8.0 (5.3)            | 8.4 (2.9) | 0.19    |
| **Smoking**       |           |                     |                      |           | <0.001  |
| Never             | 326 (51%) | 98 (55%)            | 142 (59%)            | 84 (39%)  |         |
| Former            | 232 (36%) | 60 (34%)            | 84 (35%)             | 86 (40%)  |         |
| Current           | 83 (13%)  | 20 (11%)            | 16 (7%)              | 46 (21%)  |         |
| **Drugs**         |           |                     |                      |           |         |
| Aspirin           | 326 (51%) | 82 (46%)            | 123 (51%)            | 120 (55%) | 0.19    |
| Calcium Channel Blockers | 239 (37%) | 60 (34%)          | 88 (36%)             | 89 (41%)  | 0.30    |
| Drug Category                                | Value 1 | Value 2 | Value 3 | Value 4 | Value 5 | Value 6 | P-value |
|---------------------------------------------|---------|---------|---------|---------|---------|---------|---------|
| Angiotensin-converting enzyme – inhibitor/Angiotensin II receptor blocker | 104 (16%) | 28 (16%) | 34 (14%) | 42 (19%) | 0.29    |
| Beta-blocker                                | 186 (29%) | 55 (31%) | 71 (29%) | 58 (27%) | 0.65    |
| Diuretics                                   | 106 (16%) | 29 (16%) | 56 (23%) | 21 (10%) | <0.001  |
| Lipid-lowering drugs                        | 248 (39%) | 53 (30%) | 96 (40%) | 97 (45%) | 0.008   |
| Estrogen Replacement Therapy                | 117 (27%) | 9 (5%)   | 108 (44%) | - (--)  | <0.001  |

Values are given as n (%) or mean (standard deviation). P-value shows women vs. men.
| Chr. | Significant SNP in females | Position | Gene region | Risk Allele | Overall allele X frequency | OR Overall | P-value Overall | OR Men | P-value Men | OR Premeno | P-value Premeno | OR Postmeno | P-value Postmeno |
|------|---------------------------|----------|-------------|-------------|--------------------------|------------|----------------|--------|------------|-----------|----------------|-------------|----------------|
| 1    | rs12038000                | 111859362| ADORA3      | A/G         | 0.61                     | 1.30       | 0.0357         | 0.93   | 0.7307     | 1.37      | 0.1832         | 1.73        | **0.0097**     |
| 1    | rs16851008                | 201387919| ADORA1      | G/A         | 0.87                     | 1.33       | 0.1066         | 0.79   | 0.3910     | 2.48      | 0.0792         | 1.77        | 0.0424         |
| 1    | k1_20139534               | 201395343| ADORA1/ MYBP | A/G         | 0.87                     | 1.28       | 0.1549         | 0.73   | 0.2538     | 2.88      | 0.0619         | 1.74        | 0.05           |
| 1    | rs16851020                | 201400275| MYBP/ ADORA1| C/A         | 0.87                     | 1.29       | 0.1502         | 0.70   | 0.2132     | 2.48      | 0.0792         | 1.77        | 0.0424         |
| 6    | rs7767084                 | 160882493| LPA         | G/A         | 0.16                     | 1.32       | 0.0780         | 0.71   | 0.2483     | 2.35      | 0.0058         | 1.48        | 0.1085         |
| 6    | rs9365171                 | 160901726| LPA         | A/C         | 0.35                     | 1.37       | 0.0118         | 0.99   | 0.9691     | 1.79      | 0.0213         | 1.61        | 0.0224         |
| 6    | rs3798221                 | 160918138| LPA         | T/G         | 0.19                     | 1.58       | 0.0023         | 0.80   | 0.4244     | 1.94      | 0.0115         | 2.21        | **0.0017**     |
| 6    | rs9364564                 | 160919030| LPA         | A/G         | 0.18                     | 1.50       | 0.0134         | 0.77   | 0.3854     | 1.94      | 0.0206         | 2.09        | **0.0077**     |
| 6    | rs7453899                 | 160930756| LPA         | T/A         | 0.35                     | 1.35       | 0.0167         | 1.00   | 1.0000     | 1.68      | 0.0357         | 1.58        | 0.0269         |
| 6    | rs35600881                | 160946754| LPA         | A/G         | 0.23                     | 1.50       | 0.0046         | 0.95   | 0.8481     | 1.63      | 0.0521         | 2           | **0.0029**     |
| 6    | rs13202636                | 160949718| LPA         | G/A         | 0.23                     | 1.49       | 0.0053         | 0.95   | 0.8481     | 1.62      | 0.057          | 1.99        | **0.0032**     |
| 6    | rs1321195                 | 161004146| LPA         | T/C         | 0.13                     | 1.48       | 0.0256         | 0.80   | 0.4877     | 1.82      | 0.0475         | 2.03        | 0.0148         |
| 7    | rs2237583                 | 94788113 | ONP1        | G/A         | 0.70                     | 1.15       | 0.3002         | 0.70   | 0.0898     | 1.33      | 0.3269         | 2.02        | **0.0034**     |
| 11   | rs757092                  | 2455754  | KCNQ1       | A/G         | 0.64                     | 1.2        | 0.1337         | 1.05   | 0.8214     | 2.05      | **0.0058**     | 1.02        | 0.9126         |
| 11   | rs11022996                | 2458902  | KCNQ1       | A/G         | 0.61                     | 1.15       | 0.2288         | 1.17   | 0.3798     | 1.93      | **0.0068**     | 1.08        | 0.7061         |
| 11   | rs1080017                 | 2468376  | KCNQ1       | G/A         | 0.64                     | 1.23       | 0.0935         | 1.03   | 0.8661     | 2.1       | **0.0046**     | 1.06        | 0.7654         |
| 11   | rs594942                  | 63762868 | FKBP2       | T/C         | 0.35                     | 1.18       | 0.1757         | 1.02   | 0.9067     | 1.9       | **0.0093**     | 1.02        | 0.9413         |
Table S3: SNPs associated with Macrovascular/ Epicardial Endothelial dysfunction significant only among Males

| Chr | Significant SNP in males | Position | Gene region | Risk allele X/Y frequency | OR X/Y | Overall allele X frequency | OR Overall | P-value Overall | OR Men | P-value Men | OR Premeno | P-value Premeno | OR Postmeno | P-value Postmeno |
|-----|--------------------------|----------|-------------|---------------------------|--------|---------------------------|------------|----------------|--------|-------------|-----------|----------------|------------|------------------|
| 1   | rs17511046               | 201376668| **ADORAI**  | G/A                       | 0.93   | 1.17                      | 0.5066     | **0.0068**     | 0.79   | 0.5397      | 0.55      | 0.132          |            |
| 4   | rs3774933                | 103645369| **NFKB1**   | G/A                       | 0.39   | 1.06                      | 0.6362     | **0.0085**     | 0.81   | 0.4177      | 0.78      | 0.2167         |            |
| 4   | rs1599961                | 103662599| **NFKB1**   | A/G                       | 0.39   | 1.06                      | 0.6362     | **0.0085**     | 0.81   | 0.4177      | 0.78      | 0.2167         |            |
| 6   | rs20456                  | 39432901 | LOC100124   | C/T                       | 0.43   | 1.31                      | 0.0283     | **0.0069**     | 1.35   | 0.2205      | 0.98      | 0.7137         |            |
| 6   | k6_39474093              | 39474093 | **KIF6**    | T/A                       | 0.06   | 1.95                      | 0.0060     | **0.0047**     | 1.35   | 0.5081      | 1.55      | 0.2736         |            |